Abstract
Remimazolam represents a breakthrough in paediatric anaesthesia, with predictable pharmacokinetics and safety profile. A recent study provides key dosing data for children while noting the need for comparative trials, pharmacogenetic studies, and long-term safety evaluations. We highlight its potential for broad clinical use, but call for further research to optimise its integration into paediatric anaesthesia practice.